SEC Filing Summary: PharmAthene, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by PharmAthene, Inc. on December 16, 2013. The report serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The registrant is incorporated in Delaware with principal executive offices in Annapolis, Maryland. Note: The request metadata referenced "Altimmune, Inc.," but the filing text explicitly identifies the registrant as PharmAthene, Inc.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural filing to disclose a press release and does not contain a financial statement or quantitative performance data.
Material Changes
The filing discloses the issuance of a press release on December 16, 2013, under Item 7.01 (Regulation FD). The text of the press release is attached as Exhibit 99.1 but is not included in the provided input content. Consequently, no specific material changes to operations or financial status can be summarized from the available text.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies. The document solely references the existence of the press release attached as an exhibit.
Key Facts for Investor Verification
- Verify the content of the press release attached as Exhibit 99.1, as the 8-K text only references its existence.
- Confirm the corporate identity: The filing is for PharmAthene, Inc., not Altimmune, Inc.
- Check for subsequent filings or the full text of the December 16, 2013 press release to understand the specific event triggering this report.